Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors-Reference-Cited by-同舟云学术

Plasma‐derived factor VIIa and factor X mixture agent (MC710) prophylaxis in haemophilia B patients with inhibitors

Published:2022-12-14 Issue:2 Volume:29 Page:456-465
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Sakai Michio¹,Amano Kagehiro²,Chin Motoaki³,Takedani Hideyuki⁴,Ishida Hiroyuki⁵,Sakashita Kazuo⁶,Taki Masashi⁷,Migita Masahiro⁸,Watanabe Hiroyoshi⁹,Ishimura Masataka¹⁰,Nogami Keiji¹¹,Harano Sho¹²,Shirahata Akira¹³

Affiliation:

1. Department of Pediatrics Munakata Suikokai General Hospital Fukuoka Japan

2. Department of Laboratory Medicine Tokyo Medical University Hospital Tokyo Japan

3. Department of Pediatrics Nihon University Itabashi Hospital Tokyo Japan

4. Department of Joint Surgery IMSUT Hospital The Institute of Medical Science The University of Tokyo Tokyo Japan

5. Department of Pediatrics Kyoto City Hospital Kyoto Japan

6. Department of Hematology Oncology Nagano Children's Hospital Nagano Japan

7. Department of Pediatrics St. Marianna University Hospital Kanagawa Japan

8. Department of Pediatrics Japanese Red Cross Kumamoto Hospital Kumamoto Japan

9. Department of Pediatrics Tokushima University Hospital Tokushima Japan

10. Department of Pediatrics Kyushu University Hospital Fukuoka Japan

11. Department of Pediatrics Nara Medical University Nara Japan

12. Department of Clinical Development KM Biologics Co., Ltd. Kumamoto Japan

13. Kitakyushu Yahata Higashi Hospital Fukuoka Japan

Publisher

Wiley

Subject

Genetics (clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.14710

Reference12 articles.

1. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

2. Advances in hemophilia and the role of current and emerging prophylaxis;Acharya SS;Am J Manag Care,2016

3. Factor VIII inhibitors in hemophilia A: rationale and latest evidence

4. Prevalence of factor IX inhibitors among patients with haemophilia B: results of a large-scale North American survey

5. ITI in hemophilia B: possibilities and problems;Warrier I;International Monitor of Haemophilia,2000

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Diagnosis and Treatment of Autoimmune Acquired Coagulation Factor Deficiencies: An Evidence-Based Review of Japanese Practice;Seminars in Thrombosis and Hemostasis;2024-06-12

2. Reduced plasma factor X is associated with a lack of response to recombinant activated factor VII in patients with hemophilia A and inhibitor, but does not impair emicizumab-driven hemostasis in vitro;Thrombosis Research;2024-05

3. Cerebral infarction in a patient with inhibitor-positive hemophilia B treated with plasma-derived factor VIIa and factor X mixture;Annals of Hematology;2024-04-13

4. 血友病インヒビター治療薬factor VIIa/factor X製剤の現状と展望;Japanese Journal of Thrombosis and Hemostasis;2023